Get started
Author

Anne‐Gaëlle Dosne

Observed names: A. G. Dosne, A.-G. Dosne, A.G. Dosne, Anne-Gaëlle Dosne, Anne‐Gaelle Dosne
Institution: Argenx (Belgium)
ORCID: 0000-0002-6937-0910
Observed ORCIDs: 0000-0002-6937-0910, 0000-0002-6298-8494
OpenAlex ID: A5020177847
Improving the estimation of parameter uncertainty distributions in nonlinear mixed effects models using sampling importance resampling
2016 · Anne-Gaëlle Dosne, Martin Bergstrand, et al. · Journal of Pharmacokinetics and Pharmacodynamics · 252
PDF
An automated sampling importance resampling procedure for estimating parameter uncertainty
2017 · Anne-Gaëlle Dosne, Martin Bergstrand, et al. · Journal of Pharmacokinetics and Pharmacodynamics · 149
PDF
Erdafitinib (ERDA; JNJ-42756493), a pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRa): Phase 2 continuous versus intermittent dosing.
2018 · Yohann Loriot, Andrea Necchi, et al. · Journal of Clinical Oncology · 28
A strategy for residual error modeling incorporating scedasticity of variance and distribution shape
2015 · Anne-Gaëlle Dosne, Martin Bergstrand, et al. · Journal of Pharmacokinetics and Pharmacodynamics · 28
PDF
Considerations for Industry—Preparing for the FDA Model‐Informed Drug Development (MIDD) Paired Meeting Program
2024 · Gerald R. Galluppi, Malidi Ahamadi, et al. · Clinical Pharmacology & Therapeutics · 22
PDF
dOFV distributions: a new diagnostic for the adequacy of parameter uncertainty in nonlinear mixed-effects models applied to the bootstrap
2016 · Anne-Gaëlle Dosne, Ronald Niebecker, et al. · Journal of Pharmacokinetics and Pharmacodynamics · 15
PDF
Plasma and Liver Pharmacokinetics of the N-Acetylgalactosamine Short Interfering RNA JNJ-73763989 in Recombinant Adeno-Associated–Hepatitis B Virus–Infected Mice
2022 · Louis Sandra, Huybrecht T’jollyn, et al. · Journal of Pharmacology and Experimental Therapeutics · 14
PDF
Erdafitinib’s effect on serum phosphate justifies its pharmacodynamically guided dosing in patients with cancer
2021 · Anne‐Gaëlle Dosne, Elodie Valade, et al. · CPT Pharmacometrics & Systems Pharmacology · 14
A translational model-based approach to inform the choice of the dose in phase 1 oncology trials: the case study of erdafitinib
2021 · E. M. Tosca, N. Terranova, et al. · Cancer Chemotherapy and Pharmacology · 13
Population Pharmacokinetics of Total and Free Erdafitinib in Adult Healthy Volunteers and Cancer Patients: Analysis of Phase 1 and Phase 2 Studies
2019 · Anne‐Gaelle Dosne, Elodie Valade, et al. · The Journal of Clinical Pharmacology · 13
Challenging the Norm: A Multidisciplinary Perspective on Intravenous to Subcutaneous Bridging Strategies for Biologics
2023 · Sihem Ait‐Oudhia, Yow‐Ming Wang, et al. · Clinical Pharmacology & Therapeutics · 11
Population pharmacokinetics and exposure–response analyses of daratumumab plus pomalidomide/dexamethasone in relapsed or refractory multiple myeloma
2022 · Anne‐Gaelle Dosne, Xia Li, et al. · British Journal of Clinical Pharmacology · 9
Exposure–response analyses of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma
2022 · Anne-Gaëlle Dosne, Elodie Valade, et al. · Cancer Chemotherapy and Pharmacology · 8
PDF
Assessment of the effect of erdafitinib on cardiac safety: analysis of ECGs and exposure–QTc in patients with advanced or refractory solid tumors
2019 · Elodie Valade, Anne-Gaëlle Dosne, et al. · Cancer Chemotherapy and Pharmacology · 8
Model averaging for robust assessment of QT prolongation by concentration‐response analysis
2017 · A.G. Dosne, M. Bergstrand, et al. · Statistics in Medicine · 8
Development and validation of a time-varying correction factor for QT interval assessment in drug-resistant tuberculosis patients
2025 · Thanakorn Vongjarudech, Anne-Gaëlle Dosne, et al. · International Journal of Antimicrobial Agents · 6
A Population Pharmacokinetic Model of Macitentan and Its Active Metabolite Aprocitentan in Healthy Volunteers and Patients with Pulmonary Arterial Hypertension
2021 · Roberta Bartolucci, Anne-Gaëlle Dosne, et al. · Clinical Pharmacokinetics · 5
Establishing the Exposure‐ QT Relationship During Bedaquiline Treatment Using a Time‐Varying Tuberculosis‐Specific Correction Factor ( QTcTBT )
2025 · Thanakorn Vongjarudech, Anne‐Gaëlle Dosne, et al. · CPT Pharmacometrics & Systems Pharmacology · 3
PDF
Nipocalimab Dose Selection for A Phase 3 Study in Adult Patients with Generalized Myasthenia Gravis (P1-5.018)
2023 · Juan-José Pérez-Ruixo, Yaowei Zhu, et al. · Neurology · 3
Effect of Carbamazepine on the Pharmacokinetics of Erdafitinib in Healthy Participants
2024 · Pharavee Jaiprasart, Peter Hellemans, et al. · Clinical Pharmacology in Drug Development · 2
Pharmacodynamic-Mediated Drug Disposition (PDMDD) Model of Daratumumab Monotherapy in Patients with Multiple Myeloma
2023 · Xia Li, Anne-Gaëlle Dosne, et al. · Clinical Pharmacokinetics · 2
Nipocalimab Dose Selection in Generalized Myasthenia Gravis
2025 · Belén Valenzuela, Martine Neyens, et al. · CPT Pharmacometrics & Systems Pharmacology · 1
PDF
Hyperphosphatemia due to erdafitinib (a pan-FGFR Inhibitor) and anti-tumour activity among patients (Pts) with advanced urothelial carcinoma (UC)
2019 · S. Tagawa, A. Siefker-Radtke, et al. · Annals of Oncology · 1
PDF
Advancing Evidence Generation in Small, Diverse, Understudied Population
2026 · Amitava Mitra, Anne‐Gaelle Dosne, et al. · Clinical Pharmacology & Therapeutics
PDF
Considerations for Industry—Preparing for the FDA Model-Informed Drug Development (MIDD) Paired Meeting Program
2024 · Souvik Bhattacharya, Gerald Galluppi, et al.
PDF
Works count: 28
Citation count: 615
H-index: 11
I10-index: 11
Year
Topic
Type